Renal cell carcinoma (Q56019530)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

review article

1 reference

title

Renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Bernard Escudier

0 references

author name string

Brian I Rini

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Steven C Campbell

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Bernard Escudier

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

5 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

9669

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

1119-1132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Rising incidence of renal cell cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Rising incidence of small renal masses: a need to reassess treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Vegetable and fruit consumption and risk of renal cell carcinoma: Results from the Netherlands cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

International renal‐cell cancer study. VIII. Role of diuretics, other anti‐hypertensive medications and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

International renal-cell cancer study. II. Analgesics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

The genetic basis of cancer of the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

von Hippel-Lindau disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Benign renal neoplasms in adults: cross-sectional imaging findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Changing concepts in the management of renal oncocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Renal mass biopsy--a renaissance?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Subclassification of renal cell neoplasms: an update for the practising pathologist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Histopathology and molecular genetics of renal tumors toward unification of a classification system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Renal medullary carcinoma. The seventh sickle cell nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

NEPHRON SPARING SURGERY FOR RENAL TUMORS: INDICATIONS, TECHNIQUES AND OUTCOMES

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Kidney function as a predictor of noncardiovascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Laparoscopic renal cryoablation in 32 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Renal cryoablation: outcome at 3 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Ablative techniques for the management of kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

The natural history of observed enhancing renal masses: meta-analysis and review of the world literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Solid renal tumors: an analysis of pathological features related to tumor size

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Improved prognostication of renal cell carcinoma using an integrated staging system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Hormone Treatment and Sex Steroid Receptors in Metastatic Renal Cell Carcinoma: Report of a Multicentric Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Temsirolimus, an inhibitor of mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

mTOR and cancer: insights into a complex relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960229-4

7 January 2021

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1016/S0140-6736(09)60229-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19269025%20AND%20SRC:MED&resulttype=core&format=json